MDACC Study No:2012-0188 ( NCT No: NCT01729104)
Title:A Phase I/II Study of Carfilzomib plus Lenalidomide and Rituximab in the Treatment of relapsed/refractory B-cell non-Hodgkin Lymphoma
Principal Investigator:Michael Wang
Treatment Agent:Carfilzomib; Lenalidomide; Rituximab
Study Status:Open
Study Description:The goal of Part 1 of this clinical research study is to find the highest
tolerable dose of carfilzomib that can be given in combination with
lenalidomide and rituximab to patients with relapsed or refractory B-cell
non-hodgkin lymphoma.

The goal of Part 2 of this study is to learn if the drug combination can help
to control B-cell non-hodgkin lymphoma.

The safety of this drug combination will be studied in both parts.

Carfilzomib is designed to keep cancer cells from repairing themselves. If the
cancer cells cannot repair themselves, this may cause them to die.

Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may decrease the growth of cancer cells.

Rituximab is designed to attach to cancer cells and damage them, which may
cause the cancer cells to die. It is also designed to cause the immune system
to attack cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:Carfilzomib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Celgene
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults